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INTRODUCTION
In 2009, 21,550 women were diagnosed with ova-
rian cancer and 14,600 of them died due to the
disease. The ovarian cancer was the fifth most com-
mon causes of death from malignancy. In the
United States, an estimated 1 of 72 women would
develop the ovarian cancer in their lifetime and 1
of 100 women would die because of the disease.1
In Europe, there were 61,000 new cases diagnosed
and 39,000 deaths from ovarian cancer occurred
annually.2
In Indonesia, cancer was the fifth causes of
death. It was because the life expectancy rate is in-
creased so that automatically, it will rise the de-
generative disease; one of which is cancer. Life ex-
pectancy rate is related to the improvement of so-
cioeconomic condition. More than 40% of women
malignancies are gynecological cancers.3
Advanced epithelial ovarian cancer typically pre-
sents with widely disseminated intraabdominal
disease. The standard treatment of advanced epi-
thelial ovarian cancer includes primary cytoreduc-
Abstract
Objective: To compare the outcomes and survival rate of primary
debulking surgery with neoadjuvant chemotherapy.
Method: We selected advanced ovarian cancer patients from medi-
cal records. Subjects were allocated into groups of primary debulk-
ing surgery and neoajuvant chemotherapy by considering the inclu-
sion and exclusion criteria. We analyzed the data using T test,
Fisher’s exact, and chi-square. The survival rate was presented in
Kaplan Meier curve, whereas the significance was tested with Log-
rank. We managed the data using STRATA software version 12.
Result: We obtained 32 cases of primary debulking surgery group
and 20 cases of the neoadjuvant chemotherapy group. Most of the
subjects (44.2%) were 40-49 years old and 80.8% had delivered
more than twice. The mean value of Ca-125 at admission was
3,594.8 u/ml (range 66.6 to 73,000 u/ml). Total of 31 subjects
showed the serous histologic type (59.6%). There was no associa-
tion between primary debulking surgery and neoadjuvant chemo-
therapy for the parameter of operative time, blood loss, organs in-
jury, ICU stay, and hospital stay (p>0.05). Primary debulking surgery
had a survival rate similar to neoadjuvant chemotherapy group
(p=0.95).
Conclusion: The perioperative outcomes of advanced ovarian can-
cer patients has similar result between primary debulking surgery
and neoadjuvant chemotherapy. Primary debulking surgery has a
survival rate similar to neoadjuvant chemotherapy group.
[Indones J Obstet Gynecol 2016; 4-2: 111-115]
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Abstrak
Tujuan: Membandingkan luaran dan angka kebertahanan hidup an-
tara bedah debulking primer dengan kemoterapi neoajuvan.
Metode: Peneliti mengambil pasien kanker ovarium stadium lanjut
dari rekam medik. Subjek dialokasikan ke dalam kelompok bedah de-bulking primer dan kemoterapi neoajuvan dengan mempertimbang-
kan kriteria inklusi dan eksklusi. Data dianalisis dengan uji T, Fisher
exact, dan chi-square. Angka kebertahanan hidup ditampilkan dalamkurva Kaplan Meier di mana kemaknaan diuji dengan Logrank. Kami
mengolah data menggunakan software Strata versi 12.
Hasil: Kami mendapat 32 kasus bedah debulking primer dan 20 kasus
dari kelompok kemoterapi neoajuvan. Kebanyakan subjek (44,2%)berusia 40-49 tahun dan 80,8% pernah melahirkan lebih dari 2 kali.
Rerata nilai Ca-125 saat masuk ialah 3.594,8 U/ml (66,6 hingga
73.000 U/ml). Sebanyak 31 subjek memperihatkan tipe histologi se-rosa (59,6%). Tidak ada hubungan antara bedah debulking primer
dengan kemoterapi neoajuvan untuk luaran waktu operasi, jumlahhilang darah, kerusakan organ, lama tinggal di ruang rawat intensif
maupun RS (p>0,05). Bedah debulking primer memiliki angka ke-
bertahanan hidup mirip dengan kelompok kemoterapi neoajuvan(p=0,95).
Kesimpulan: Luaran pasien kanker ovarium stadium lanjut yang di-lakukan bedah debulking primer mirip dengan yang dilakukan kemo-
terapi neoajuvan. Bedah debulking primer memiliki angka kebertaha-nan hidup mirip dengan kelompok kemoterapi neoajuvan.
[Maj Obstet Ginekol Indones 2016; 4-2: 111-115]
Kata kunci: bedah debulking primer, kanker ovarium stadium lanjut,
kemoterapi neoajuvan
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tion or debulking surgery followed by adjuvant
systemic chemotherapy.1 Surgical cytoreduction of
advanced stage ovarian cancer, also termed "tumor
debulking", is defined as an attempt to maximally
resect all visible and palpable disease.4
The ideally curative surgical approach to the
cancer is through en-bloc resection of the tumor
with wide margin of normal tissue. Unluckily, this
method is not appropriate to most of ovarian can-
cer patients due to the existence of diffuse metas-
tases to vital structures at the time of diagnosis.
Therefore, the aim for these patients is to reduce
the tumor burden as much as possible.5
The most effective surgical cytoreduction in-
tends to reach the minimal risk of residual status.
The microscopic residual disease has correlation
with the overall survival rate in patients with ad-
vanced disease.1,6
 In selected cases which it predicts that complete
or optimal surgical cytoreduction will not be
achieved at primary surgery, we should perform
the neoadjuvant chemotherapy followed by inter-
val debulking surgery (delayed primary surgery).
Recent study showed that neoadjuvant chemothe-
rapy followed by interval debulking surgery in the
bulky stage III and stage IV disease was not inferior
to primary surgery.7
Some gynecologist has suggested this approach,
especially for the treatment of stage IV ovarian can-
cer or for patients with very high metastatic tumor
load (for example the mass was more than 1,000
grams) or in patients with poor general condition.8
Several advantages of neoadjuvant chemotherapy
are such as a reduced risk of perioperative mor-
bidity, a higher rate of optimal resection, and the
contention that survival is not compromised by de-
ferring the initial attempt at surgical debulking.9
Interval debulking surgery in patients with ad-
vanced stage of ovarian cancer offered the same
chance of survival as primary debulking surgery;
however, interval debulking surgery showed better
toleration.10 Therefore, this study aims to compare
the outcomes of primary debulking surgery with
neoadjuvant chemotherapy.




Mean of age ­ years old 49.1 48.7 0.55*
Parity ­ N (%)
Nulliparity 1 (3.1) 2 (10.0) 0.55**
Primiparity 4 (12.5) 3 (15.0)
Multiparity 27 (84.4) 15 (75.0)
FIGO stage ­ N (%)
IIIC 29 (90.6) 15 (75.0) 0.24***
IV 3 (9.4) 5 (25.0)
Mean of serum Ca­125 at entry (U/ml) 1661.9 6687.36 0.05*
Histologic type ­ N (%)
Serous 16 (50) 15 (75.0) 0.19**
Endometrioid 9 (28.1) 3 (15.0)
Mucinous 3 (9.4) 2 (10.0)
Clear cell 4 (12.5) 0
Histologic grade ­ N (%)
Well differentiated 3 (9.4) 5 (25.0)
Moderately differentiated 15 (46.9) 8 (40.0)
Poorly differentiated 14 (43.8) 7 (35.0)
Degree of cytoreduction ­ N (%)
Complete macroscopic resection 9 (28.1) 9 (45.0) 0.44**
Optimal cytoreduction 5 (15.6) 3 (15.0)
Suboptimal cytoreduction 18 (56.3) 8 (40.0)
*t-test, **chi-square, ***fisher exact
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METHODS
We obtained the data from stage IIIC and IV epi-
thelial ovarian cancer patients’ medical record.
Each patient was classified into the group of pri-
mary debulking surgery and neoadjuvant chemo-
therapy. We needed 30 samples of each group. The
perioperative outcomes were consisted of duration
of surgery, intraoperative blood loss, intraopera-
tive organs injury, length of stay in intensive care
unit (ICU), and also the total hospitalization time.
We analyzed the data using T test for the nu-
merical data and Fisher’s exact also chi-square for
the categorical data. The survival rate for both
groups were calculated from the date of surgery to
death (event). Survival rate was presented in
Kaplan Meier curve, whereas the significance was
tested with Logrank. We managed the data using
STRATA software version 12.
RESULTS
We could not fulfill the required samples due to
the difficulty of searching the medical records. In
our study, we obtained 32 cases of primary debulk-
ing surgery group and 20 cases of the neoadjuvant
chemotherapy group. Most of the subjects (44.2%)
were 40-49 years old and 80.8% had delivered
more than twice. The mean value of Ca-125 at ad-
mission was 3,594.8 u/ml (range 66.6 to 73,000
u/ml). Total of 31 subjects showed the serous his-
tologic type (59.6%). The characteristics of pa-
tients were distributed in Table 1.
In our study, there was no association between
primary debulking surgery and neoadjuvant che-
motherapy for the parameter of operative time,
blood loss, organs injury, ICU stay, and hospital
stay (Table 2). Figure 1 described the overall sur-
vival rates based on treatment options.







Mean 244.8 229.5 0.70
Range 105-510 165-375
Blood loss rate (ml)
Mean 1,704.7 1,152.5 0.66
Range 300-13,000 400-2,100
Organs injury ICU stay (days) 3 1 0.57
Mean 0.3 0.3 0.57
Range 0-2 0-2
Hospital stay (days)
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Figure 1. Overall Survival Rate According to the Treatment Options.
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DISCUSSION
Length of Surgery
Hou, et al. showed that the average length of sur-
gery was significantly lower in the neoadjuvant
chemotherapy compared with primary debulking
surgery group (211 min vs. 276 min, p<0.001).11
However, a study by Hegazy, et al. indicated the
conflicting result where the average duration of the
operation on neoadjuvant group was 150 minutes,
while for primary surgery group was over 190
minutes. There was no significant difference bet-
ween two groups in statistic.12 Their result was
similar to Kuhn, et al. study. Kuhn said that the
average length of surgery for primary debulking
surgery and neoadjuvant chemotherapy were 270
and 260 minutes. They found no significant rela-
tionship on length of surgery between two
groups.13 Our study had similar results with study
by Hegazy et al. and Kuhn et al. The average length
of surgery was 245 minutes versus 230 minutes,
also we found no significant difference in duration
of surgery between two groups (p=0.70).
Blood Loss Rates
Hou, et al. studied 172 patients of advanced stage
epithelial ovarian cancer consisting of 109 patients
performing the primary debulking surgery and 63
patients undergoing the neoadjuvant chemothe-
rapy from 1998 to 2005. Patients receiving neoad-
juvant chemotherapy experienced significantly less
blood loss during surgery (p<0.001).11 The same
result was also reported by Hegazy, et al. They re-
ported that the group with neoadjuvant chemo-
therapy had significantly less blood loss during sur-
gery (p=0.02).12 Our study found the average blood
loss in the neoadjuvant chemotherapy group was
1,152.5 ml, while the primary debulking surgery
group was 1,704.7 ml. Clinically, the amount of
bleeding was higher in the primary debulking sur-
gery group; yet the statistical test had shown no
difference between the two groups (p=0.34).
Organs Injury
Kuhn, et al. in a retrospective study involving stage
IIIC ovarian cancer patients including 31 patients
received neoadjuvant chemotherapy and 32 pa-
tients were allocated to the primary debulking sur-
gery group. The result showed that 11 and 9
women were found injured at the primary debulk-
ing surgery and neoadjuvant chemotherapy group.
They did not find the difference in intraoperative
organs injury.13 Similar result was reported by
Hegazy, et al. where they did not find a significant
association between therapy modality and intra-
operative organs injury.12 Our study released the
similar result to both study above.
Hospital and ICU Stay
Hegazy, et al in their study showed that neoadju-
vant chemotherapy group was shorter in length of
hospital (p=0.05) and ICU stay (p=0.03) signifi-
cantly.12 Contrary to the result stated by Hegazy,
et al., Hou, et al., in their study involving 172 pa-
tients, they concluded that there was no significant
association between administration of neoadjuvant
chemotherapy and length of stay in hospital also
ICU.11 Of all the perioperative outcome variables,
neoadjuvant chemotherapy group experienced
shorter operative time, less blood loss, and shorter
treatment duration. Neoadjuvant chemotherapy
group offered better clinical outcome compared
with primary debulking surgery despite lack of sta-
tistical evidence.
Overall Survival Rate
Vergote, et al. in a multicenter study involving 718
patients, reported that the median overall survival
rate of primary debulking surgery group was 29
months, whereas in the neoadjuvant chemothe-
rapy group was 30 months. There was no statistical
difference in survival rate between the two groups
(p=0.98).14 Hegazy, et al. also declared similar re-
sult to study stated above. Primary debulking sur-
gery group had median overall survival rate of 28
months, whereas in the chemotherapy group was
25 months; however, it was not statistically dif-
ferent (p=0.5).12 Loizzi, et al. in a case-control study
examined the outcomes of primary debulking sur-
gery and neoadjuvant chemotherapy in advanced
ovarian cancer. The result did not differ statisti-
cally. (p=0.66).15 Steed, et al. also reported that
there was no significant difference in terms of pro-
gression-free survival (PFS) (HR=1.61; p=0.04;
95% CI=1.03-2.53) and overall survival (OS)
(HR=1.85; p=0.03, 95% CI=1.06 - 3.23) rate for
both groups. It was the only one study that stating
both groups had the same survival rate.16 Our
study also confirmed that both groups had the
same overall survival rate.
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CONCLUSION
The perioperative outcomes of advanced ovarian
cancer patients has similar result between primary
debulking surgery and neoadjuvant chemotherapy.
However, through clinical judgement, neoadjuvant
chemotherapy group has better perioperative out-
comes compared with primary surgery group. Pri-
mary debulking surgery has a survival rate similar
with neoadjuvant chemotherapy group.
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